Abstract
To investigate the mode of action of the new hypolipoproteinemic compound Terbufibrol (4’- [3-(4’-t-butylphenoxy)-2-hydroxy-propoxy] benzoic acid) the effect on hepatic HMG-CoA reductase (EC 1.1.1.34) and 7-α-hydroxylase (EC 1.14) activity was studied in comparison to Clofibrate (CPIB). Male Wistar rats were conditioned to controlled day-time feeding and then pretreated orally with the test drugs. In these animals Terbufibrol was at least twice as active as CPIB lowering serum total cholesterol (TC). HMG-CoA reductase was assayed in 10 000xg and 7-α-hydroxylase in 18 000 xg supernatants of liver homogenate by following the incorporation of 14C-acetate (14C-mevalonate) into cholesterol (Ch) and the conversion of 14C-Ch to 7-α-hydroxy-Ch, respectively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Löser, R., Steffen, I., Kussmaul, M. (1978). Mode of Action of Terbufibrol (INN), A New Hypolipemic Agent. In: Deutsche Pharmakologische Gesellschaft. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-39532-5_18
Download citation
DOI: https://doi.org/10.1007/978-3-662-39532-5_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-38666-8
Online ISBN: 978-3-662-39532-5
eBook Packages: Springer Book Archive